|Bid||0.2601 x 1000|
|Ask||0.2518 x 4000|
|Day's range||0.2503 - 0.3079|
|52-week range||0.2080 - 1.9700|
|Beta (5Y monthly)||2.03|
|PE ratio (TTM)||N/A|
|Earnings date||10 Aug 2022 - 15 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.98|
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentation at the New York Academy of Sciences (NYAS) Frontiers in Cancer Immunotherapy Conference in New York, NY.
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.